Consolidated Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Sales revenue	$ 0	$ 0
Cost of goods sold	0	0
Gross profit (loss)	0	0
General and administrative expenses	1,868,734	2,001,617
LOSS FROM OPERATIONS	(1,868,734)	(2,001,617)
OTHER INCOME (EXPENSE)
Gain on extinguishment	22,405	467,872
Gain on settlement of accounts payable	0	422,414
Gain on deconsolidation	5,206,208	0
Interest expense	(474,768)	(1,285,460)
Loss on modification of line of credit	0	(650,000)
Loss on impairment of note receivable	(3,025,000)	0
Debt default penalty	0	(286,059)
Loss on disposal	(15,639)	0
Other income	9,000	0
Total other income/(expense)	1,722,206	(1,331,233)
LOSS BEFORE INCOME TAXES	(146,528)	(3,332,850)
Income tax expense (Note 8)	0	0
LOSS FROM CONTINUING OPERATIONS	(146,528)	(3,332,850)
Net loss from discontinued operations (Note 4)	(384,345)	(392,177)
NET LOSS	(530,873)	(3,725,027)
Net loss attributable to common stockholders of GB Sciences, Inc. - basic and diluted
Continuing operations, basic	146,528	3,332,850
Discontinued operations, basic	384,345	392,177
Net loss	$ (530,873)	$ (3,725,027)
Net loss per common share – basic and diluted
Continuing operations (in dollars per share)	$ (0.00)	$ (0.01)
Discontinued operations (in dollars per share)	(0.00)	(0.00)
Net loss (in dollars per share)	$ (0.00)	$ (0.01)
Weighted average common shares outstanding - basic and diluted (in shares)	317,621,942	285,190,729